AR120038A1 - ANTI-NRP1A ANTIBODIES AND THEIR USES TO TREAT EYE DISEASES - Google Patents

ANTI-NRP1A ANTIBODIES AND THEIR USES TO TREAT EYE DISEASES

Info

Publication number
AR120038A1
AR120038A1 ARP200102648A ARP200102648A AR120038A1 AR 120038 A1 AR120038 A1 AR 120038A1 AR P200102648 A ARP200102648 A AR P200102648A AR P200102648 A ARP200102648 A AR P200102648A AR 120038 A1 AR120038 A1 AR 120038A1
Authority
AR
Argentina
Prior art keywords
nrp1a
antibodies
eye diseases
treat eye
treat
Prior art date
Application number
ARP200102648A
Other languages
Spanish (es)
Inventor
Nina Zippel
Pankaj Gupta
Fei Han
Yining Huang
Sarah Low
Juergen Prestle
Leo Thomas
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of AR120038A1 publication Critical patent/AR120038A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Anticuerpos y fragmentos de estos que actúan sobre el domino A de Neuropilina-1 (Nrp1A). Más específicamente, anticuerpos anti-Nrp1A y métodos de uso para el tratamiento de varias enfermedades o trastornos.Antibodies and fragments of these that act on the A domain of Neuropilin-1 (Nrp1A). More specifically, anti-Nrp1A antibodies and methods of use for the treatment of various diseases or disorders.

ARP200102648A 2019-09-24 2020-09-23 ANTI-NRP1A ANTIBODIES AND THEIR USES TO TREAT EYE DISEASES AR120038A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP19199099 2019-09-24

Publications (1)

Publication Number Publication Date
AR120038A1 true AR120038A1 (en) 2022-01-26

Family

ID=68066567

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP200102648A AR120038A1 (en) 2019-09-24 2020-09-23 ANTI-NRP1A ANTIBODIES AND THEIR USES TO TREAT EYE DISEASES

Country Status (2)

Country Link
AR (1) AR120038A1 (en)
EC (1) ECSP22020678A (en)

Also Published As

Publication number Publication date
ECSP22020678A (en) 2022-04-29

Similar Documents

Publication Publication Date Title
CL2019001874A1 (en) Context-permissive isoform-specific tgfß1 inhibitors and their use.
CL2019003636A1 (en) Aadc polynucleotides for the treatment of parkinson's disease.
ES2692773T3 (en) Treatments for fibrosis
CL2017000285A1 (en) Combined therapy for the treatment of a paramyxovirus
PE20210488A1 (en) ANTIBODIES SPECIFIC TO GUCY2C AND ITS USES
CL2019000935A1 (en) Pharmaceutical composition, methods for treatment and uses thereof.
CO2021014768A2 (en) Anti-sema3a antibodies and their uses to treat eye diseases
CO2018005393A2 (en) Anti-htra1 antibodies and methods of use thereof
AR115583A1 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF LIVER DISEASES AND DISORDERS
CO2020014510A2 (en) Selective treg stimulator rur20kd-il-2 and related compositions
CO2021004141A2 (en) Modulators of pnpla3 expression
CL2019001749A1 (en) Use of anti-sclerostin antibodies in the treatment of imperfect osteogenesis.
CL2019002574A1 (en) Modulators of pcsk9 expression.
AR113618A1 (en) ANTIMICROBIAL PEPTIDES AND METHODS TO USE THEM
CL2021000930A1 (en) Novel Pyridazines
CO2021007006A2 (en) Modulators of irf5 expression
MX2022006073A (en) Methods of use of anti-trem2 antibodies.
BR112021017550A2 (en) Al amyloidosis treatment methods
CL2021002866A1 (en) Headache treatment using anti-cgrp antibodies.
UY38472A (en) FOXP3 EXPRESSION MODULATORS
CO2020003134A2 (en) Modulators of enac expression
BR112018012126A2 (en) "adjuvant, method for preventing and / or treating an autoimmune disease, and use of an adjuvant"
EA202191058A1 (en) ANTIBODIES AGAINST MUCIN-16 AND METHODS OF THEIR APPLICATION
AR120038A1 (en) ANTI-NRP1A ANTIBODIES AND THEIR USES TO TREAT EYE DISEASES
CO2022003324A2 (en) Anti-nrp1a antibodies and their uses to treat eye diseases